Cargando…
Effectiveness and Safety of a Single-Dose Ivermectin Treatment for Uncomplicated Strongyloidiasis in Immunosuppressed Patients (ImmunoStrong Study): The Study Protocol
Strongyloidiasis affects an estimated 600 million people worldwide, especially in tropical and subtropical areas. Single-dose ivermectin treatment has shown to be effective among immunocompetent patients with uncomplicated strongyloidiasis. Here, we present the protocol of the ImmunoStrong study, a...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308528/ https://www.ncbi.nlm.nih.gov/pubmed/34199000 http://dx.doi.org/10.3390/pathogens10070812 |
_version_ | 1783728302279622656 |
---|---|
author | Salvador, Fernando Lucas-Dato, Ana Roure, Silvia Arsuaga, Marta Pérez-Jacoiste, Asunción García-Rodríguez, Magdalena Pérez-Molina, José A. Buonfrate, Dora Saugar, José María Molina, Israel |
author_facet | Salvador, Fernando Lucas-Dato, Ana Roure, Silvia Arsuaga, Marta Pérez-Jacoiste, Asunción García-Rodríguez, Magdalena Pérez-Molina, José A. Buonfrate, Dora Saugar, José María Molina, Israel |
author_sort | Salvador, Fernando |
collection | PubMed |
description | Strongyloidiasis affects an estimated 600 million people worldwide, especially in tropical and subtropical areas. Single-dose ivermectin treatment has shown to be effective among immunocompetent patients with uncomplicated strongyloidiasis. Here, we present the protocol of the ImmunoStrong study, a prospective observational study aiming to evaluate the effectiveness and safety of a single-dose ivermectin for treatment of uncomplicated strongyloidiasis in immunosuppressed patients. The secondary objectives are to assess accuracy of molecular techniques for the follow-up of these patients and to determine the population pharmacokinetics of ivermectin. The information retrieved by this study will cover relevant information gaps in the strongyloidiasis management among immunosuppressed patients. |
format | Online Article Text |
id | pubmed-8308528 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83085282021-07-25 Effectiveness and Safety of a Single-Dose Ivermectin Treatment for Uncomplicated Strongyloidiasis in Immunosuppressed Patients (ImmunoStrong Study): The Study Protocol Salvador, Fernando Lucas-Dato, Ana Roure, Silvia Arsuaga, Marta Pérez-Jacoiste, Asunción García-Rodríguez, Magdalena Pérez-Molina, José A. Buonfrate, Dora Saugar, José María Molina, Israel Pathogens Study Protocol Strongyloidiasis affects an estimated 600 million people worldwide, especially in tropical and subtropical areas. Single-dose ivermectin treatment has shown to be effective among immunocompetent patients with uncomplicated strongyloidiasis. Here, we present the protocol of the ImmunoStrong study, a prospective observational study aiming to evaluate the effectiveness and safety of a single-dose ivermectin for treatment of uncomplicated strongyloidiasis in immunosuppressed patients. The secondary objectives are to assess accuracy of molecular techniques for the follow-up of these patients and to determine the population pharmacokinetics of ivermectin. The information retrieved by this study will cover relevant information gaps in the strongyloidiasis management among immunosuppressed patients. MDPI 2021-06-27 /pmc/articles/PMC8308528/ /pubmed/34199000 http://dx.doi.org/10.3390/pathogens10070812 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Study Protocol Salvador, Fernando Lucas-Dato, Ana Roure, Silvia Arsuaga, Marta Pérez-Jacoiste, Asunción García-Rodríguez, Magdalena Pérez-Molina, José A. Buonfrate, Dora Saugar, José María Molina, Israel Effectiveness and Safety of a Single-Dose Ivermectin Treatment for Uncomplicated Strongyloidiasis in Immunosuppressed Patients (ImmunoStrong Study): The Study Protocol |
title | Effectiveness and Safety of a Single-Dose Ivermectin Treatment for Uncomplicated Strongyloidiasis in Immunosuppressed Patients (ImmunoStrong Study): The Study Protocol |
title_full | Effectiveness and Safety of a Single-Dose Ivermectin Treatment for Uncomplicated Strongyloidiasis in Immunosuppressed Patients (ImmunoStrong Study): The Study Protocol |
title_fullStr | Effectiveness and Safety of a Single-Dose Ivermectin Treatment for Uncomplicated Strongyloidiasis in Immunosuppressed Patients (ImmunoStrong Study): The Study Protocol |
title_full_unstemmed | Effectiveness and Safety of a Single-Dose Ivermectin Treatment for Uncomplicated Strongyloidiasis in Immunosuppressed Patients (ImmunoStrong Study): The Study Protocol |
title_short | Effectiveness and Safety of a Single-Dose Ivermectin Treatment for Uncomplicated Strongyloidiasis in Immunosuppressed Patients (ImmunoStrong Study): The Study Protocol |
title_sort | effectiveness and safety of a single-dose ivermectin treatment for uncomplicated strongyloidiasis in immunosuppressed patients (immunostrong study): the study protocol |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308528/ https://www.ncbi.nlm.nih.gov/pubmed/34199000 http://dx.doi.org/10.3390/pathogens10070812 |
work_keys_str_mv | AT salvadorfernando effectivenessandsafetyofasingledoseivermectintreatmentforuncomplicatedstrongyloidiasisinimmunosuppressedpatientsimmunostrongstudythestudyprotocol AT lucasdatoana effectivenessandsafetyofasingledoseivermectintreatmentforuncomplicatedstrongyloidiasisinimmunosuppressedpatientsimmunostrongstudythestudyprotocol AT rouresilvia effectivenessandsafetyofasingledoseivermectintreatmentforuncomplicatedstrongyloidiasisinimmunosuppressedpatientsimmunostrongstudythestudyprotocol AT arsuagamarta effectivenessandsafetyofasingledoseivermectintreatmentforuncomplicatedstrongyloidiasisinimmunosuppressedpatientsimmunostrongstudythestudyprotocol AT perezjacoisteasuncion effectivenessandsafetyofasingledoseivermectintreatmentforuncomplicatedstrongyloidiasisinimmunosuppressedpatientsimmunostrongstudythestudyprotocol AT garciarodriguezmagdalena effectivenessandsafetyofasingledoseivermectintreatmentforuncomplicatedstrongyloidiasisinimmunosuppressedpatientsimmunostrongstudythestudyprotocol AT perezmolinajosea effectivenessandsafetyofasingledoseivermectintreatmentforuncomplicatedstrongyloidiasisinimmunosuppressedpatientsimmunostrongstudythestudyprotocol AT buonfratedora effectivenessandsafetyofasingledoseivermectintreatmentforuncomplicatedstrongyloidiasisinimmunosuppressedpatientsimmunostrongstudythestudyprotocol AT saugarjosemaria effectivenessandsafetyofasingledoseivermectintreatmentforuncomplicatedstrongyloidiasisinimmunosuppressedpatientsimmunostrongstudythestudyprotocol AT molinaisrael effectivenessandsafetyofasingledoseivermectintreatmentforuncomplicatedstrongyloidiasisinimmunosuppressedpatientsimmunostrongstudythestudyprotocol |